Interventions of Interest: Intensity modulated radiation therapy for prostate cancer Prostate cancer is the most common nondermatologic cancer in men. In 2006, approximately230,000 new patients in the United States were diagnosed with prostate cancer and 27,000 men died of the disease. The major treatment options for localized prostate cancer include external beam radiation therapy, brachytherapy, […]
Interventions of Interest: Brachytherapy and Proton beam therapy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas been focused […]
ICER developed a report on Active Surveillance and Radical Prostatectomy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas […]
Interventions of Interest: enzalutamide (Xtandi®, Astellas and Medivation) abiraterone acetate (Zytiga®, Janssen) apalutamide (Erleada™, Janssen). October 2018 Review ICER developed a report on anti-androgen drugs for high risk prostate cancer. The added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits for patients. For questions or additional information, […]
Intervention of interest: Proton beam therapy ICER completed a Technology Assessment of proton beam therapy (PBT) for the public meeting of the Washington State Health Care Authority Clinical Committee. ICER’s review found that PBT was superior to surgical treatment of tumors of the eye, and appears to be a safer alternative to conventional radiation in […]
Interventions of Interest: The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for ide-cel, the only CAR-T agent having received FDA approval at this time, a majority of panelists voted that it represents […]
Interventions of Interest: nadofaragene firadenovec (Adstiladrin®, FKD Therapies Oy and FerGene) oportuzumab monatox (Vicineum®, Sesen Bio) Bladder cancer is the most common cancer involving the urinary system and usually presents with blood in the urine (hematuria). Overall, bladder cancer is the sixth most common cancer in the United States (US), with approximately 80,000 new cases […]